日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Global cancer statistics for children: Two decades of change and projections to 2050

全球儿童癌症统计数据:二十年来的变化及至2050年的预测

Li, Wangzhong; Huang, Shanzhou; Chen, Qiyue; Wang, Ting; Lu, Guanming; Niu, Xing; Song, Qiong; Xu, Yilin; Mo, Ke; Cui, Chunhui; Zhang, Run; Du, Wei; He, Feiying; Shi, Lei; Lin, Yan; Wei, Qiu; Jiang, Li; Chen, Yongsheng; Song, Baiyang; Zhang, Huijuan; Fu, Zhenli; Liao, Wenjing; Sun, Jiancong; Guan, Wenhui; Zhuang, Weitao; Zhong, Nanshan; Zhou, Chengzhi; Liang, Wenhua; Kang, Min; He, Jianxing

Hematopoietic Stem-Cell Gene Therapy for Cystinosis

胱氨酸病的造血干细胞基因治疗

Barshop, Bruce A; Ball, Edward D; Benador, Nadine; Trauner, Doris; Phillips, Susan; Dohil, Ranjan; Afshari, Natalie A; Roy, Sohini; Campo Fernandes, Beatriz; Kohn, Donald; Shayan, Katayoon; Everett, John K; Bushman, Frederic D; Midgley, Julian; Liang, Hong; Sawyers, Anne; Gangoiti, Jon A; Panchal, Maulik; Ahmed, Imama; Cherqui, Stephanie

MALDI Matrix: Origins, Innovations, and Frontiers

MALDI矩阵:起源、创新与前沿

Wu, Ran; Liu, Rui; Hu, Hao; Qin, Liang; Chen, Lulu; Bao, Zhibin; Fu, Jinxiang; Guo, Hua; Wang, Lei; Wang, Anna; Wang, Zihan; Yang, Chenyu; Cheng, Xiangrui; Chen, Difan; Liu, Haiqiang; Jing, Yanping; Guo, Shuai; Fu, Yujie; Wang, Xiaodong

Tenecteplase for Acute Non-Large Vessel Occlusion 4.5 to 24 Hours After Ischemic Stroke: The OPTION Randomized Clinical Trial

替奈普酶治疗缺血性卒中后 4.5 至 24 小时内的急性非大血管闭塞:OPTION 随机临床试验

Ma, Gaoting; Mo, Ran; Zuo, Yingting; Ma, Qingfeng; Zhao, Guangjian; Yao, Xiaoxi; Liang, Ji; Zhou, Li; He, Yong; Long, Faqing; Yuan, Zhengzhou; Liu, Lei; Han, Guosheng; Tan, Yan; Ai, Zhibing; Cai, Chunsheng; Liu, Juan; Zhang, Liyong; Yang, Haihua; Yi, Tingyu; Li, Li; Fu, Yao; Zhang, Yanxing; Shao, Xiangzhong; Yu, Zhipeng; Wu, Saizhen; Du, Yanqiu; Mao, Lingqun; Guo, Hongling; Chen, Xufeng; Chen, Yifei; Zhao, Qiong; Chi, Liyi; Liu, Yi; Zhang, Haochun; Li, Guangzong; Meng, Shujuan; Wu, Yifan; Wu, Jieying; Jiang, Ziying; Lei, Shaoyuan; Gao, Daiquan; Zhong, Lianmei; Fiehler, Jens; Wang, Duolao; Nguyen, Thanh N; Saver, Jeffrey L; Hao, Junwei

Metabolic dysfunction-associated steatotic liver disease accelerates pancreatic cancer progression and metastasis via the macrophage migration inhibitory factor-CD44 axis

代谢功能障碍相关的脂肪肝疾病通过巨噬细胞迁移抑制因子-CD44轴加速胰腺癌的进展和转移。

Yu, Qian; Song, Hui; Shi, Xiao-Ya; Zhu, Liang; Liang, Yu; Gong, Rui-Ning; Dong, Xiao-Wu; Liu, Shang-Long; Wang, Hai-Zhen; Wang, Ying-Luo; Cui, Jiu-Fa; Yang, Xiao-Nan; Chen, Ying; Gao, Chao; Yang, Zhan; Zhu, Qing-Tian; Li, Chang; Zhang, Huan; Ying, Jie-Er; Zheng, Mei-Fang; Tian, Yan-Tao; Hu, Hai-Tao; Shao, Xin-Xin; Li, Yue; Mo, Ming-Guang; Lu, Yun; Ma, Zheng; Fu, Shun-Li; Niu, Qing-Hui; Liao, Yuan-Yu; Zhao, Chen-Yang; Liu, Xin; Saluja, Ashok K; Wang, Ji-Gang; Li, Xiao-Yu; Guo, Song-Yue; Wang, Wei-Hua; Wang, Song; Liu, Bin; Lu, Guo-Tao; Ren, He

Chemo-photothermal synergy ignites antitumor immunity via ferroptosis

化疗-光热协同作用通过铁死亡激活抗肿瘤免疫。

Lin, Jundong; Yang, Huikang; Zou, Zhihao; Deng, Lizhi; Cai, Xiaoxia; Chen, Muqi; Xu, Jiaquan; Yin, Wenjun; Wen, Biyan; Xie, Wenjie; Xu, Qianfeng; Zhong, Guowei; Wu, Zhenjie; Chen, Yanfei; Zhang, Rihong; Tian, Weicheng; Zhang, Yixun; Long, Yusen; Li, Yize; Han, Zhaodong; Liang, Yuxiang; Ye, Jianheng; Lu, Jianming; Liang, Yingke; Dai, Qishan; Zou, Fen; He, Huichan; Zhong, Weide; Zhuo, Yangjia

Esophageal cancer: from pathogenesis to precision therapies

食管癌:从发病机制到精准治疗

Zhang, Shaosen; Shen, Yanrong; Zhu, Lingxuan; Lai, Yancheng; Zhu, Liang; Xiao, Xinyi; Li, Jiachen; Tan, Wen; Lin, Dongxin; Wu, Chen

Remodeling the tumor dormancy ecosystem to prevent recurrence and metastasis

重塑肿瘤休眠生态系统以防止复发和转移

Liang, Yu; Chen, Wo-Ming; Zhang, Youming; Li, Lei

DUSP6 ablation restores CAR T-cell fitness impaired by tumor CD58 loss through invigoration of AP-1 signaling

DUSP6 消融可通过增强 AP-1 信号传导来恢复因肿瘤 CD58 丢失而受损的 CAR T 细胞活性。

Ma, Xinran; Zhang, Yang; Wang, Yao; Han, Fuxin; Lu, Yuting; Tong, Chuan; Guo, Yelei; Wei, Jianshu; Zhu, Qi; Dong, Liang; Cao, Zhi; Meng, Zhenzhen; Shi, Jinhong; Wu, Zhiqiang; Han, Weidong

First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial

一线治疗EGFR突变型非小细胞肺癌患者,比较奥莫替尼(EGFR酪氨酸激酶抑制剂)联合阿帕替尼(VEGFR抑制剂)与奥莫替尼单药治疗的疗效:一项随机、多中心、II期临床试验

Zhang, Fan; Zheng, Zhendong; Zhang, Hongmei; Yan, Xiaolong; Liu, Zhefeng; Yang, Fan; Wen, Juyi; Gan, Xin; Wu, Lin; Cang, Shundong; Wang, Hongmei; Zhao, Jun; Peng, Liang; Li, Xiaosong; Fan, Zaiwen; Shen, Ge; Zhou, Qiong; Zou, Jinjing; Xu, Yu; Zhang, Lei; Zhao, Mingfang; Cai, Shangli; Hu, Yi